Pediatric Vaccines Market 2021 : Explore Future Growth GlaxoSmithKline Plc., Merck & Co, Pfizer, Sanofi S.A

The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than 2 years old. Other vaccines for infants include, Hepatitis B vaccine, flu vaccine, and human papillomavirus vaccine.

The global pediatric vaccine market is estimated to account for US$ 37,567 Mn in terms of value in 2019 and is expected to reach US$ 98,859 Mn by the end of 2027.

Request PDF Brochure of this report:
https://www.coherentmarketinsights.com/insight/request-pdf/1708

Drivers

Increasing funding related to vaccines is expected to boost growth of the global pediatric vaccines market over the forecast period. For instance, in January 2020, Codagenix, a company focused on R&D of vaccines and viral therapies raised US$ 20 million in a new round of financing led by Adjuvant Capital.

Opportunities

Players in the market may focus on targeting developing regions for launching essential vaccines. The prevalence of tuberculosis is high in such regions. Moreover, increasing resistance of antibiotics used to treat tuberculosis is also expected to offer lucrative growth opportunities for players in the market.

Key Takeaways:

Pneumococcal Vaccine sub segment in the vaccine type segment in global pediatric vaccines market was valued at US$ 10,299.7 Mn in 2018 and is expected to reach US$ 36,120.1 Mn by 2027 at a CAGR of 14.4% during the forecast period.

Increasing partnership among Global Alliance for Vaccines and Immunization (GAVI) and key vendors to deliver pneumococcal vaccines in emerging countries is expected to be a significant growth factor for the market. For instance, in March 2016, GSK (Glaxo Smith Kline) announced the introduction of pneumococcal vaccine at the lowest price - US$ 3.05 from 2017, a reduction of 10% from the 2016 price (US$ 3.40).

The conjugate vaccines segment held dominant position in the global pediatric vaccine market in 2018, accounting for 30.0% share in terms of value, followed by live vaccines and inactivated vaccine, respectively.

The monovalent vaccines segment held dominant position in the global pediatric vaccine market in 2018, accounting for 76.6% share in terms of value, followed by multivalent vaccine, respectively.

Majority of the newely approved pediatric vaccines, as well as existing pediatric vaccines for different diseases are monovalent vaccines. Monovalent vaccines provide protection from an individual disease.

Request Here Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/1708

Market Trends

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in November 2019, Takeda Pharmaceutical Company Limited announced publication of results from the primary endpoint analysis of its Phase 3 Tetravalent Immunization against Dengue Efficacy Study trial of its dengue vaccine candidate (TAK-003) in the New England Journal of Medicine.

Major players in the market are also focused on developing new vaccines. For instance, in November 2019, NewLink Genetics Corporation received the European Commission (EC) approval for marketing ERVEBO or Zaire Ebola virus vaccine V920 across 31 European countries.

Competitive Landscape

Major players operating in the global pediatric vaccine market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Pancea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.

Key Developments

December 2019: Y-mAbs Therapeutics Inc. received a Rare Pediatric Disease Designation status for its GD2-GD3 vaccine for the treatment of neuroblastoma, from the U.S. FDA

December 2019: Seqirus received approval for its cell-based quadrivalent influenza vaccine FLUCELVAX QUAD for the protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains, from Health Canada

Segmentation:

By Vaccine Type:
Pneumonococcal Vaccine
DTP Vaccine
Rotavirus Vaccine
MMR Vaccine
Polio Vaccine
Influenza Vaccine
Hepatitis B Vaccine
Meningococcal Vaccine
Hib Vaccine
Varicella Vaccine

By Technology:
Live or Attenuated Vaccine
Inactivated or Killed Vaccine
Toxoid Vaccine
Conjugate Vaccine
Subunit Vaccine
Recombinant Vaccine

By Type:
Monovalent Vaccine
Multivalent Vaccine

By Distribution Channel:
Government
Private

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount for Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/insight/buy-now/1708

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.